PMV Pharmaceuticals' Series C Round

PMV Pharmaceuticals raised a round of funding on November 13, 2019.

PMV Pharma is developing first-in-class p53 and p53 pathway modulators for the treatment of cancer. p53 is the most commonly mutated gene in cancer, with over 50 percent of all human tumors containing…

Articles about PMV Pharmaceuticals' Series C Round: